Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001.
about
Epidemiology of hepatitis C virus infectionEffects of reduction in heroin supply on injecting drug use: analysis of data from needle and syringe programmesWhat's in a virus? Folk understandings of hepatitis C infection and infectiousness among injecting drug users in Kings Cross, SydneyThe impact of changes to heroin supply on blood-borne virus notifications and injecting related harms in New South Wales, Australia.Variation in hepatitis C services may lead to inequity of heath-care provision: a survey of the organisation and delivery of services in the United KingdomAn autoregressive integrated moving average model for short-term prediction of hepatitis C virus seropositivity among male volunteer blood donors in Karachi, PakistanTreatment responses in Asians and Caucasians with chronic hepatitis C infectionInterferon-free combination therapies for the treatment of hepatitis C: current insightsA systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt.An evidence synthesis approach to estimating Hepatitis C prevalence in England and Wales.A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design.Hepatic and extra-hepatic sequelae, and prevalence of viral hepatitis C infection estimated from routine data in at-risk groups.Living with Hepatitis C Virus: A Systematic Review and Narrative Synthesis of Qualitative Literature.The "lessons" of the Australian "heroin shortage".Blood-borne viruses and their survival in the environment: is public concern about community needlestick exposures justified?Management of chronic hepatitis C virus infection: a new era of disease control.Treatment for hepatitis C virus infection among current injection drug users in Australia.Risk factors for hepatitis C infection and perception of antibody status among male prison inmates in the Hepatitis C Incidence and Transmission in Prisons Study cohort, Australia.The acceptability and feasibility of peer worker support role in community based HCV treatment for injecting drug users.Quantifying hepatitis C transmission risk using a new weighted scoring system for the Blood-Borne Virus Transmission Risk Assessment Questionnaire (BBV-TRAQ): applications for community-based HCV surveillance, education and prevention.Chronic hepatitis C virus infection: genotyping and its clinical role.Incident Hepatitis C Virus Genotype Distribution and Multiple Infection in Australian PrisonsHepatitis C and diabetes: the inevitable coincidence?Chronic hepatitis C virus infection in children and adolescents: Epidemiology, natural history, and assessment of the safety and efficacy of combination therapy.An overview about hepatitis C: a devastating virus.Review of models used to predict the future numbers of individuals with severe hepatitis C disease: therapeutic and cost implications.Efficacy and cost of a hepatocellular carcinoma screening program at an Australian teaching hospital.Irritability: an underappreciated side effect of interferon treatment for chronic hepatitis C?Nurse-led clinic: effective and efficient delivery of assessment and review of patients with hepatitis B and C.Modeling hepatitis C virus transmission among people who inject drugs: Assumptions, limitations and future challenges.Exploration of potential mechanisms of hepatitis C virus resistance in exposed uninfected intravenous drug users.The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam.High incidence of hepatitis C virus reinfection within a cohort of injecting drug users.Modelling the past, current and future HCV burden in France: detailed analysis and perspectives.Health-related quality of life in children with hepatitis C acquired in the first year of life.The burden of hepatitis C in England.Estimates and projections of hepatitis B-related hepatocellular carcinoma in Australia among people born in Asia-Pacific countries.Anti-envelope antibody responses in individuals at high risk of hepatitis C virus who resist infectionHepatitis C-induced hepatocyte apoptosis following liver transplantation is enhanced by immunosuppressive agents.Health workers' support for hepatitis C treatment uptake among clients with a history of injecting.
P2860
Q22305500-9B318A8A-0D54-4626-B851-37A85907FD1DQ24563558-708A6594-24FD-4137-8D7C-665FD1D3F3ADQ24795489-0141FFFE-921A-4A22-9E3C-40C71EAD7C22Q24811537-DEBE76D6-1A7D-4E00-A4EF-62CAA05BFADAQ25256731-4BE0A9B0-D60D-48C2-A811-6EBFFB755689Q27488317-2A82A83D-D105-47E3-B019-771BDC0EC066Q27489011-17D4BD02-7508-42F1-B536-BAC650160E4AQ28087400-3538A047-90FF-4D2F-825B-37A9F23F364FQ30403548-FE16ACC9-4D98-484F-BC17-089C323CE3C2Q33387534-D85D2942-BA1D-48EA-B1F1-7165BF2CD023Q33483115-7B7054A4-DAC2-4770-97BE-150ECA2898CFQ33559091-3C53C0FF-A318-4166-A744-17922A87AEF0Q33654457-58E1682F-3952-450B-BB77-55F964412335Q34880536-78DE20CC-FED2-4605-B6D4-7BE12FE06E72Q35628991-504DF6F8-4A32-4F25-862E-DE8594374ED7Q35823410-F2AF39C7-80FA-4CB4-BE3C-0CE968D9EA76Q36071304-487FCB96-DBF9-48E8-BB3A-6971ED5D9114Q36272388-50CDC8BC-CFA5-4BC4-8EA9-9446D22FCD38Q36535234-CF3F3D7D-2E3A-4212-9D04-FD58165655A8Q36663249-72941A5A-E121-4920-AFAD-212211F830B6Q36895749-8C69F8A8-329D-4A9B-8E7D-43C4513D5182Q37040556-A2317425-3632-46DC-89AA-2AA74291E11CQ37432092-304A0F8D-1B94-4BE6-AFC4-93CBC8E31545Q37561618-17A0AAA7-DDAA-4ECA-BC30-9D94BC460FEFQ37719516-E8813D1B-FAC7-477D-82A0-C188D6DB186BQ37763157-C977F587-7CA3-420C-9E0B-71DC374953ADQ37764965-F7DE91E0-4195-49A7-8056-2E2A1D554974Q37849332-1101BC2A-345D-4A47-A7E6-2C62F2F96030Q38194651-3952853B-7FB2-4442-98F1-F607406F4056Q38573508-E177536C-3A94-4D0B-844A-B494EE993E34Q39285745-948EA989-76C3-4706-87FE-A67ECAB85667Q39707313-D993D9DE-7DEC-4768-B6E6-AF75F5D069B3Q39797179-0F4031B8-60A4-46DE-AE96-0688DFCCC682Q40024651-D51C5E7B-670F-49EA-9FC8-04926337D6A5Q40121760-2B915DD4-FC45-4356-8429-3C6BC98BA993Q40190683-B062C496-DE23-46C5-A340-29AAF7FD2E12Q40197931-41591F9F-24FF-48D7-B355-46C853CB892FQ40471338-546C142F-D245-4FB8-A87B-E8A9CB854CE9Q40679311-6FC18D29-D98F-482B-9F86-E16D48AE24D3Q40789247-70C7A56C-C03E-4A36-A3D1-485E2BFCC8D5
P2860
Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Modelling hepatitis C virus in ...... m sequelae in Australia, 2001.
@en
type
label
Modelling hepatitis C virus in ...... m sequelae in Australia, 2001.
@en
prefLabel
Modelling hepatitis C virus in ...... m sequelae in Australia, 2001.
@en
P2093
P50
P356
P1476
Modelling hepatitis C virus in ...... m sequelae in Australia, 2001.
@en
P2093
Alex Wodak
Gregory J Dore
Jenean Spencer
John Kaldor
Matthew G Law
Nick Crofts
Nicky Bath
Stuart Loveday
Wendy Giles
P304
P356
10.1093/IJE/DYG101
P577
2003-10-01T00:00:00Z